AMN Healthcare Reports Strong Q4 2025 Earnings with Labor Disruption Revenue Surge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Source: seekingalpha
AMN Healthcare's stock rose by 10.71% as it reached a 5-day high, reflecting positive market sentiment following its earnings report.
The company reported Q4 2025 revenue of $748 million, a 2% year-over-year increase, and $18 million above guidance, driven by robust performance in labor disruption revenue. Although the adjusted EBITDA decreased by 27% year-over-year, the net loss improved significantly from $188 million last year to $8 million, indicating effective cost control. Management's optimistic outlook for Q1 2026 revenue, projected between $1.225 billion and $1.24 billion, further supports confidence in future growth despite anticipated gross margin impacts.
This strong performance highlights AMN's resilience in a competitive healthcare market and its strategic investments in AI technology to enhance operational efficiency, positioning the company for sustainable growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMN
Wall Street analysts forecast AMN stock price to fall
5 Analyst Rating
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 35.770
Low
22.00
Averages
23.50
High
25.00
Current: 35.770
Low
22.00
Averages
23.50
High
25.00
About AMN
AMN Healthcare Services, Inc. is a provider of total talent solutions for healthcare organizations across the United States. The Company provides access to a comprehensive network of quality healthcare professionals through its recruitment strategies and breadth of career opportunities. Its segments include nurse and allied solutions, physician and leadership solutions, and technology and workforce solutions. The nurse and allied solutions segment include its travel nurse staffing, labor disruption staffing, local staffing, international nurse permanent placement, and allied staffing businesses. The physician and leadership solutions segment includes its locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement businesses. The technology and workforce solutions segment includes the Company’s language services, vendor management systems (VMS), workforce optimization, and outsourced solutions businesses.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AMN Healthcare Schedules Q2 2026 Earnings Call
- Earnings Call Scheduled: AMN Healthcare has scheduled a conference call for August 6, 2026, at 5:00 PM ET to discuss its Q2 2026 financial results and Q3 outlook, reflecting the company's commitment to transparency and investor communication.
- Earnings Release Timing: The company plans to issue its earnings news release at approximately 4:15 PM on the same day, allowing investors to access critical information promptly, which aids in making informed investment decisions.
- Diverse Participation Options: Investors can join the call via a live webcast or by telephone, with registration links provided, ensuring that a broader range of stakeholders can conveniently participate in the discussion, enhancing interaction between the company and its investors.
- Company Background: AMN Healthcare is a leader in total talent solutions for healthcare, reaching over 13 million patients across more than 2,300 healthcare systems in 2025, underscoring its significant position and influence in the industry.
See More
AMN Healthcare Schedules Q2 2026 Earnings Call
- Earnings Call Scheduled: AMN Healthcare has scheduled a conference call for August 6, 2026, at 5:00 p.m. ET to discuss its Q2 2026 financial results and Q3 outlook, demonstrating the company's commitment to transparency and investor communication.
- Earnings Release Timing: The company plans to issue its earnings news release on the same day at approximately 4:15 p.m. ET, allowing investors to access critical information promptly to make informed investment decisions.
- Diverse Participation Options: Investors can join the call via a live webcast or telephone, with registration links provided, ensuring broad accessibility and convenience, reflecting the company's focus on investor relations.
- Company Background: AMN Healthcare is a leader in total talent solutions for healthcare, serving over 13 million patients across more than 2,300 healthcare systems in 2025, highlighting its significant position and influence in the industry.
See More
AMN Healthcare Director Sells 3,681 Shares Indirectly
- Indirect Share Sale: Mark G. Foletta, a director at AMN Healthcare, indirectly sold 3,681 shares for approximately $114,000 on June 15, 2026, indicating a strategic liquidity management approach in the market.
- Transaction Context: This marks Foletta's first open-market sale since 2023, executed under a pre-established Rule 10b5-1 trading plan adopted on March 12, 2026, suggesting that the sale was not influenced by short-term market fluctuations.
- Ownership Structure Change: Following the sale, Foletta retains an indirect position of 17,917 shares through the family trust, with no direct holdings or derivative securities, reflecting confidence in the company's long-term prospects.
- Market Performance and Outlook: AMN's stock has risen approximately 40.9% over the past year, and while management anticipates a 4% to 6% year-over-year revenue decline in Q2, the company's improved financial health and operational performance indicate a strengthening competitive position in the healthcare sector.
See More
AMN Healthcare Director Sells Shares
- Share Sale Details: Mark G. Foletta, a director at AMN Healthcare Services, sold 3,681 indirectly held shares on June 15, 2026, for approximately $114,000, representing 17% of his total holdings, reducing his indirect ownership from 21,598 to 17,917 shares, indicating a strategic adjustment in his investment.
- Transaction Context: This sale marks Foletta's first open-market transaction since 2023; however, with nearly 18,000 shares still held, investors are advised not to overinterpret this insider sale, suggesting continued confidence in the company's prospects.
- Performance Recovery Signs: AMN Healthcare's stock has rebounded roughly 41% over the past year, driven by first-quarter results that exceeded expectations, with revenue doubling to $1.38 billion and adjusted EBITDA soaring 159% to $166.1 million, reflecting strong operational execution in the healthcare sector.
- Future Outlook and Challenges: While management anticipates a 4% to 6% year-over-year revenue decline in the second quarter, indicating an uneven recovery, the company's strengthened balance sheet and improved operational performance suggest a significantly better competitive position compared to a year ago, raising questions about sustaining growth momentum.
See More
Three Russell 2000 Stocks to Avoid
- QuidelOrtho Underperformance: Formed from the 2022 merger of Quidel and Ortho Clinical Diagnostics, QuidelOrtho (market cap $960.8 million) has shown disappointing revenue performance over the past two years, indicating its product offerings are not resonating with customers, while its free cash flow margin has shrunk by 23 percentage points over five years, suggesting increased capital consumption to remain competitive.
- AMN Healthcare Demand Weakness: AMN Healthcare (market cap $1.19 billion) has seen a decline in travelers on assignment over the past two years, indicating soft demand, and its earnings per share have contracted by 7.1% annually, creating headwinds for stock prices as increasing competition erodes profitability.
- Nabors Industries Cost Risks: Operating one of the largest land-based drilling fleets globally, Nabors Industries (market cap $1.51 billion) faces challenges with a low gross margin of 39% and a poor free cash flow margin of 2.3% over the last five years, limiting its ability to invest in growth initiatives and indicating vulnerability due to high extraction costs and unfavorable asset economics.
- Small-Cap Investment Risks: Small-cap stocks in the Russell 2000 face greater challenges due to their instability and limited resources, making stock selection critical for investors, particularly for those companies showing underperformance, necessitating careful consideration of their long-term profitability and market competitiveness.
See More
AMN Healthcare Acquires Jaide Health to Enhance Language Services
- Acquisition Announcement: AMN Healthcare announced on Tuesday its acquisition of Jaide Health, aimed at enhancing language access services to improve communication efficiency throughout the patient care journey, particularly in administrative and non-clinical interactions.
- Technological Advantage: Jaide Health's platform provides real-time language support, ensuring smooth communication during patient intake and discharge while maintaining the use of qualified human interpreters for complex clinical conversations, thereby enhancing overall service quality.
- Market Expansion: This acquisition will broaden AMN's language service capabilities, covering all aspects before and after clinical encounters, further strengthening its competitive position in the healthcare industry to meet diverse patient needs.
- Team Integration: The Jaide Health team will join AMN Healthcare, leveraging their expertise and technology to drive innovation and development in the medical translation and interpretation sector.
See More
AMN Healthcare Schedules Q2 2026 Earnings Call
- Earnings Call Scheduled: AMN Healthcare has scheduled a conference call for August 6, 2026, at 5:00 PM ET to discuss its Q2 2026 financial results and Q3 outlook, reflecting the company's commitment to transparency and investor communication.
- Earnings Release Timing: The company plans to issue its earnings news release at approximately 4:15 PM on the same day, allowing investors to access critical information promptly, which aids in making informed investment decisions.
- Diverse Participation Options: Investors can join the call via a live webcast or by telephone, with registration links provided, ensuring that a broader range of stakeholders can conveniently participate in the discussion, enhancing interaction between the company and its investors.
- Company Background: AMN Healthcare is a leader in total talent solutions for healthcare, reaching over 13 million patients across more than 2,300 healthcare systems in 2025, underscoring its significant position and influence in the industry.
See More
AMN Healthcare Schedules Q2 2026 Earnings Call
- Earnings Call Scheduled: AMN Healthcare has scheduled a conference call for August 6, 2026, at 5:00 p.m. ET to discuss its Q2 2026 financial results and Q3 outlook, demonstrating the company's commitment to transparency and investor communication.
- Earnings Release Timing: The company plans to issue its earnings news release on the same day at approximately 4:15 p.m. ET, allowing investors to access critical information promptly to make informed investment decisions.
- Diverse Participation Options: Investors can join the call via a live webcast or telephone, with registration links provided, ensuring broad accessibility and convenience, reflecting the company's focus on investor relations.
- Company Background: AMN Healthcare is a leader in total talent solutions for healthcare, serving over 13 million patients across more than 2,300 healthcare systems in 2025, highlighting its significant position and influence in the industry.
See More
AMN Healthcare Director Sells 3,681 Shares Indirectly
- Indirect Share Sale: Mark G. Foletta, a director at AMN Healthcare, indirectly sold 3,681 shares for approximately $114,000 on June 15, 2026, indicating a strategic liquidity management approach in the market.
- Transaction Context: This marks Foletta's first open-market sale since 2023, executed under a pre-established Rule 10b5-1 trading plan adopted on March 12, 2026, suggesting that the sale was not influenced by short-term market fluctuations.
- Ownership Structure Change: Following the sale, Foletta retains an indirect position of 17,917 shares through the family trust, with no direct holdings or derivative securities, reflecting confidence in the company's long-term prospects.
- Market Performance and Outlook: AMN's stock has risen approximately 40.9% over the past year, and while management anticipates a 4% to 6% year-over-year revenue decline in Q2, the company's improved financial health and operational performance indicate a strengthening competitive position in the healthcare sector.
See More
AMN Healthcare Director Sells Shares
- Share Sale Details: Mark G. Foletta, a director at AMN Healthcare Services, sold 3,681 indirectly held shares on June 15, 2026, for approximately $114,000, representing 17% of his total holdings, reducing his indirect ownership from 21,598 to 17,917 shares, indicating a strategic adjustment in his investment.
- Transaction Context: This sale marks Foletta's first open-market transaction since 2023; however, with nearly 18,000 shares still held, investors are advised not to overinterpret this insider sale, suggesting continued confidence in the company's prospects.
- Performance Recovery Signs: AMN Healthcare's stock has rebounded roughly 41% over the past year, driven by first-quarter results that exceeded expectations, with revenue doubling to $1.38 billion and adjusted EBITDA soaring 159% to $166.1 million, reflecting strong operational execution in the healthcare sector.
- Future Outlook and Challenges: While management anticipates a 4% to 6% year-over-year revenue decline in the second quarter, indicating an uneven recovery, the company's strengthened balance sheet and improved operational performance suggest a significantly better competitive position compared to a year ago, raising questions about sustaining growth momentum.
See More
Three Russell 2000 Stocks to Avoid
- QuidelOrtho Underperformance: Formed from the 2022 merger of Quidel and Ortho Clinical Diagnostics, QuidelOrtho (market cap $960.8 million) has shown disappointing revenue performance over the past two years, indicating its product offerings are not resonating with customers, while its free cash flow margin has shrunk by 23 percentage points over five years, suggesting increased capital consumption to remain competitive.
- AMN Healthcare Demand Weakness: AMN Healthcare (market cap $1.19 billion) has seen a decline in travelers on assignment over the past two years, indicating soft demand, and its earnings per share have contracted by 7.1% annually, creating headwinds for stock prices as increasing competition erodes profitability.
- Nabors Industries Cost Risks: Operating one of the largest land-based drilling fleets globally, Nabors Industries (market cap $1.51 billion) faces challenges with a low gross margin of 39% and a poor free cash flow margin of 2.3% over the last five years, limiting its ability to invest in growth initiatives and indicating vulnerability due to high extraction costs and unfavorable asset economics.
- Small-Cap Investment Risks: Small-cap stocks in the Russell 2000 face greater challenges due to their instability and limited resources, making stock selection critical for investors, particularly for those companies showing underperformance, necessitating careful consideration of their long-term profitability and market competitiveness.
See More
AMN Healthcare Acquires Jaide Health to Enhance Language Services
- Acquisition Announcement: AMN Healthcare announced on Tuesday its acquisition of Jaide Health, aimed at enhancing language access services to improve communication efficiency throughout the patient care journey, particularly in administrative and non-clinical interactions.
- Technological Advantage: Jaide Health's platform provides real-time language support, ensuring smooth communication during patient intake and discharge while maintaining the use of qualified human interpreters for complex clinical conversations, thereby enhancing overall service quality.
- Market Expansion: This acquisition will broaden AMN's language service capabilities, covering all aspects before and after clinical encounters, further strengthening its competitive position in the healthcare industry to meet diverse patient needs.
- Team Integration: The Jaide Health team will join AMN Healthcare, leveraging their expertise and technology to drive innovation and development in the medical translation and interpretation sector.
See More
